Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives Average Rating of “Hold” from Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have earned a consensus rating of “Hold” from the eight analysts that are covering the company, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $36.50.

A number of research firms have weighed in on LKFT. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings upgraded Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a research note on Thursday, February 26th. Zacks Research lowered Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “strong sell” rating in a research note on Friday, May 8th. Royal Bank Of Canada increased their target price on Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a research note on Tuesday, February 24th. Finally, Raymond James Financial reiterated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, February 24th.

Lakefront Biotherapeutics American Depositary Shares Price Performance

Shares of NASDAQ LKFT opened at $27.73 on Thursday. The business’s 50 day moving average is $28.87 and its two-hundred day moving average is $31.42. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $26.42 and a 1-year high of $37.78. The stock has a market capitalization of $1.83 billion, a P/E ratio of -19.67 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 earnings per share for the quarter. The company had revenue of $1.06 billion for the quarter. As a group, equities research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.32 earnings per share for the current fiscal year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

A number of large investors have recently modified their holdings of LKFT. Jane Street Group LLC boosted its holdings in shares of Lakefront Biotherapeutics American Depositary Shares by 2,245.7% in the first quarter. Jane Street Group LLC now owns 110,783 shares of the biotechnology company’s stock valued at $2,783,000 after purchasing an additional 115,946 shares during the period. Geode Capital Management LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at approximately $220,000. Jump Financial LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at approximately $692,000. Boothbay Fund Management LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at approximately $612,000. Finally, Engineers Gate Manager LP purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at approximately $560,000. Hedge funds and other institutional investors own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.